Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed
Status:
Completed
Trial end date:
2016-09-30
Target enrollment:
Participant gender:
Summary
This study aims to assess a fixed-dose regimen of activated prothrombin complex concentrate
(FEIBA VH, Baxter) versus the variable, manufacturer recommended, dose regimen of inactivated
prothrombin complex concentrate (Kcentra, CSL Behring) for reversal of warfarin-associated
major hemorrhage.